These differences include relatively earlier onset in BRCA1 than BRCA2 germline mutation carriers, and a relatively better survival in patients with BRCA2 than BRCA1 mutation-associated tumors in comparison to that in patients with wtBRCA-associated ovarian cancer [6,15]. Here, BRCA1 is linked to ovarian cancer.